Spring Works Therapeutics (SWTX) PT Raised to $104 at Wedbush
- Nasdaq set for worst day in 2 months before big tech earnings
- Tesla (TSLA) Gains on Q2 Beat, Analysts Mostly Positive but Others Cautious
- China's Meituan (MPNGF) Plunges 17.6% to Push Hang Seng Index to 8-Month Lows as Heavy Selling Continues
- Raytheon (RTX) Gains on Beat-and-Raise, CEO Says Next War Will Be Fought in Cyber Space and Then Outer Space
- Dollar eases slightly with Fed in focus
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
Wedbush analyst David Nierengarten raised the price target on Spring Works Therapeutics (NASDAQ: SWTX) to $104.00 (from $100.00) while maintaining a Outperform rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SpringWorks Therapeutics Inc. (SWTX) Appoints Dr. James Cassidy as Chief Medical Officer
- Larsen & Toubro Ltd. (LT:IN) (LTOUF) PT Raised to INR1,865 at Daiwa Securities
- Larsen & Toubro Ltd. (LT:IN) (LTOUF) PT Raised to INR1,970 at Investec
Create E-mail Alert Related CategoriesAnalyst PT Change
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!